Nonresponse to bridging therapy and high lymphocyte count were predictive of parkinsonism and nonrelapse mortality (NRM) after treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti) in ...
AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript February 4, 2026 AbbVie Inc. beats earnings expectations. Reported ...
NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and ...
Insilico Medicine has received investigational new drug clearance from the US Food and Drug Administration for ISM8969, an oral, brain-penetrant inhibitor of the NOD-like receptor family pyrin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results